The efficacy of dulaglutide in diabetic patients
Phase 4
- Conditions
- Type2 diabetic patients
- Registration Number
- JPRN-UMIN000019975
- Lead Sponsor
- Kawashima Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Patients having infectious diseases, thyroid disease, or malignant tumors. Patients being treated with steroids.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary end-point is plasma glucose, glycated albumin or HbA1c measurement twelve weeks after new, additional administration of dulaglutide and change from other GLP-1 receptor agonist in type 2 diabetic patients.
- Secondary Outcome Measures
Name Time Method Other laboratory data and adverse events will be analyzed as well.